A Clinical Study of a Standardized Extract of Leaves of Dalbergia sissoo (Roxb ex DC) in Postmenopausal Osteoporosis

Report: Council for Ayurveda Research - Industry Roundtable and Global Consortium for Collaborative Research in Ayurveda, 2021

The Council for Ayurveda Research (CAR) organized a three-day international event titled 'Global Consortium for Collaborative Research in Ayurveda (GCCRA) from September 17 to 19, 2021. The Consortium event was preceded by a pre-conference Industry Round Table (IRT), on September 16, 2021. The IRT and GCCRA events hosted industry heads, Ayurveda and integrative scholars and subject matter experts from several countries. The event's main objective was to initiate, facilitate, and conduct classical and cutting-edge research in Ayurveda and identify current gaps in research and research methodologies. The idea was also to develop consensus on key research areas. It was decided to form a Council for Ayurveda Research-Industrial Conclave (CAR-IC) to foster and support research on the industry side, with regular periodic meetings to enable dialogs and exchange of information and thoughts. Similarly, a Council for Ayurveda Research-Global Consortium for Collaborative Research in Ayurveda (CAR-GCCRA) was incepted to lead the initiative for providing clear, contemporary, and futuristic directions to research in the practice side of Ayurveda.

Nobiletin-loaded micelles reduce ovariectomy-induced bone loss by suppressing osteoclastogenesis

Background

Nobiletin (NOB), a polymethoxy flavonoid, possesses anti-cancer and anti-inflammatory activities, has been reported that it played role in anti-osteoporosis treatment. However, previous research did not focus on practical use due to lack of hydrophilicity and cytotoxicity at high concentrations. The aim of this study was to develop a therapeutic formulation for osteoporosis based on the utilization of NOB.

Methods

In this study, NOB-loaded poly(ethylene glycol)-block-poly(e-caprolactone) (NOB-PEG-PCL) was prepared by dialysis method. The effects on osteoclasts and anti-osteoporosis functions were investigated in a RANKL-induced cell model and ovariectomized (OVX) mice.

Results

Dynamic light scattering and transmission electron microscopy examination results revealed that the NOB-PEG-PCL had a round shape, with a mean diameter around 124 nm. The encapsulation efficiency and drug loading were 76.34±3.25% and 7.60±0.48%, respectively. The in vitro release of NOB from NOB-PEG-PCL showed a remarkably sustained releasing characteristic and could be retained at least 48 hrs in pH 7.4 PBS. Anti-osteoclasts effects demonstrated that the NOB-PEG-PCL significantly inhibited the formation of tartrate-resistant acid phosphatase (TRAP)-positive multinuclear cells stimulated by RANKL. Furthermore, the NOB-PEG-PCL did not produce cytotoxicity on bone marrow-derived macrophages (BMMs). The mRNA expressions of genetic markers of osteoclasts including TRAP and cathepsin K were significantly decreased in the presence of NOB-PEG-PCL. In addition, the NOB-PEG-PCL inhibited OC differentiation of BMMs through RANKL-induced MAPK signal pathway. After administration of the NOB-PEG-PCL, NOB-PEG-PCL prevented bone loss and improved bone density in OVX mice. These findings suggest that NOB-PEG-PCL might have great potential in the treatment of osteoporosis.

Conclusion

The results suggested that NOB-PEG-PCL micelles could effectively prevent NOB fast release from micelles and extend circulation time. The NOB-PEG-PCL delivery system may be a promising way to prevent and treat osteoporosis.